Download S1 Table.

S1Table. Baseline characteristics of included study
Regimens
Author
Ref.
Journal
Country of study
Drug resistance
Culture
Particip
Male sex
weight
HIV-positive
CD4 count
cavitation
Duration
Follow-up
condition
medium
ants
no.(%)
(mean±SD)
Age
(mean±SD)
no.(%)
median (IQR)
no.(%)
(month)
(month)
Susceptible to R, Z, M.
LJ solid
277
186 (67)
------
------
60(28)
------
------
6
6
Resistant to H: 9.0%.
medium
146
91 (62)
34.1±11.9
56.2±9.9
5(3)
------
101(69)
6
18
381
275(72)
31 (26, 40)a
------
41(11)
221(112, 334)
283(74)
6
6
101
271(27)
40
------
1015(100)
------
------
6, 9
26.2b
1674
1166(70)
------
------
123(7)
------
1170(70)
4, 6
18
416
108 (26)
------
43.6
0
------
------
4, 6
28, 30m
593
379(64)
------
------
158(27)
314(253, 441)
------
4, 6
12-18
Inclusion Criteria
compared
Age ≥18y,
Am. J.
sputum-positive TB, less
Burman et al.
24
Respir. Crit.
Africa, North America
HRZE; HRZM
than 7d fluoroquinolone
2006
Care. Med.
antibiotic or anti-TB
treatment within 6m.
Age ≥18y, drug sensitive,
Conde et al.
smear-positive TB
20
Lancet
Brazil
HRZE; HRZM
2009
without previous
LJ solid and
Susceptible to H, R, E.
liquid media
treatment.
Age ≥18 years,
Am. J.
Dorman et al.
North America, Brazil, South
19
Respir. Crit.
2009
sputum-positive TB,
Susceptible to H, R, Z,
LJ solid and
without previous
M.
liquid media
HRZE; MRZE
Africa, Spain, Uganda
Care. Med.
treatment.
Age ≥18 years with HIV，
El-Sadr et al.
Clin. Infect.
14
1998
LJ solid
culture-confirmed TB,
United States
HRZE; HRZELo
Dis.
Susceptible to H, R.
meidum
less than 1 month anti-TB
chemotherapy.
South Africa, India, Tanzania,
Gillespie et al.
N. Engl. J.
18
2014
Age ≥18y, smear-positive
Susceptible to R, M.
TB, previously untreated,
Resistant to H: 7%; Z
susceptible to R and FQs.
2%.
HRZE; HRZM;
Kenya, Thailand, Malaysia,
Med.
LJ solid and
MRZE
Zambia, China, Mexico
liquid media
Age≥18y, newly
diagnosed,
Jawahar et al
Susceptible to H, R, E,
HRZE; HRZM;
23
PLoS One
South India
2013.
sputum-positive
HRZG
O: 90.9%. Resistant to
LJ solid media
HIV-negative TB
patients.
any drug: 9.1%.
Age>18y，weight ≥35 kg,
Jindani et al.
N. Engl. J.
South Africa, Zimbabwe,
Med.
Botswana, and Zambia
17
2014
LJ solid and
smear-positive, less than
HRZE; MRZE
Susceptible to H, R, M
1 month anti-TB
chemotherapy.
liquid media
Age ≥18 years, newly
Kennedy et al.
Am Rev
12
1993
Susceptible to H, R, E,
Northern Tanzania
HRZE, HRC
diagnosed, smear-positive
LJ solid media
20
10 (50)
30.3
------
40%
------
------
2
2
168
115(68)
34.8
49.3±7.66
58(35)
------
107(64)
6
12
1692
1230(73)
------
------
304(18)
------
857(51)
4, 6
28, 30
217
145(67)
31.5±9.1
55.2±7.9
127(59)
204(94)
6
6
------
3, 4, 6
27, 28, 30
Respir Dis
TB.
C.
Age ≥18 y, newly
Kennedy et al.
Clin. Infect.
11
1996
Susceptible to H, R, Z,
Tanzania
HRZE; HRC
LJ solid
diagnosed, smear-positive
Dis.
meidum
TB.
E, C
Age: 18-65y, newly
Merle et al.
N. Engl. J.
Benin, Guinea, Kenya, Senegal,
22
2014
Susceptible to R, Z, E,
HRZE; HRZG
Med.
diagnosed sputum
Durban
LJ solid meida
G. Resistant to H: 5.5%.
positive TB.
Age: 18-65y, weight:
Int. J.
Rustomjee et
13
Tuberc.
HRZE; HRZG;
38-80 kg, newly
HRZM; HRZO
diagnosed, smear-positive
KwaZulu Natal
al. 2008
LJ solid and
Susceptible to R.
246.7(100,
liquid midia
348)
Lung. Dis.
TB.
Age ≥18 y,
Susceptible to H, R, E,
Velayutham et
Clin Infect
21
al. 2014
smear-positive TB
South India
Dis
HRZE; HRZEM
without HIV, less than 1
month treatment.
O: 86.4%. Resistant to
any drug: 13.6%.
H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; C: ciprofloxacin; O: ofloxacin; Lo: levofloxacin; M: modifloxacin; G: gatifloxacin; FQs: fluroquinolones.
LJ: Löwenstein-Jensen
IQR = interquartile range
a
: results expressed as median (IQR)
b
: median follow-up time
LJ solid media
780
198 (25)
------
------
0
------